Login / Signup

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial.

Richard Bruce WarrenAdam ReichAndrzej KaszubaWaldemar PlacekChristopher E M GriffithsJihao ZhouBruce RandazzoPaul LizzulJohann E Gudjonsson
Published in: The British journal of dermatology (2023)
Imsidolimab demonstrated a rapid and sustained resolution of symptoms and pustular eruptions in subjects with GPP. It was generally well-tolerated, associated with acceptable safety, and is advancing to Phase 3 trials. These data support targeting of IL-36 signalling with a specific antibody, imsidolimab, as a therapeutic option for this severely debilitating condition. The study was registered under EudraCT Number 2017-004021-33 and NCT03619902.
Keyphrases